Similar Papers

Paper Title
Journal
Date
Author
‘Small’ randomised neo-adjuvant chemotherapy trials in breast cancer reporting on pathological response: more harm than good?
H Bonnefoi
Annals of Oncology | VOL. 16
H BonnefoiH Bonnefoi
02 Aug 2005
Neoadjuvant treatment for operable breast cancer in the community: Applications of cooperative group trials
R A Somer ... E Rodler
Journal of Clinical Oncology | VOL. 26
R A Somer, et. al.R A Somer ... E Rodler
20 May 2008
269P - Neoadjuvant Chemotherapy in Operable Breast Cancer: Data From the Aster Study (At for 3 Cycles Followed by CMF for 3 Cycles)
E Puma ... A Moliterni
Annals of Oncology | VOL. 23
E Puma, et. al.E Puma ... A Moliterni
01 Sep 2012
Neoadjuvant Treatment of Breast Cancer
Michael Untch ... Gunter Von Minckwitz
Breast Care | VOL. 6
Michael Untch, et. al.Michael Untch ... Gunter Von Minckwitz
01 Dec 2011
View more papers

More From: Journal of Clinical Oncology

Paper Title
Journal
Date
Author
Letetresgene Autoleucel in Advanced/Metastatic Myxoid/Round Cell Liposarcoma
Sandra P D'Angelo ... Neeta Somaiah
Journal of Clinical Oncology | VOL. -
Sandra P D'Angelo, et. al.Sandra P D'Angelo ... Neeta Somaiah
21 Jan 2025
De-Escalation Strategies With Immune Checkpoint Blockers in Non–Small Cell Lung Cancer: Do We Already Have Enough Evidence?
Jordi Remon ... Benjamin Besse
Journal of Clinical Oncology | VOL. -
Jordi Remon, et. al.Jordi Remon ... Benjamin Besse
21 Jan 2025
Reply to: Automatic for the People: What Has Machine Learning Analysis of Positron Emission Tomography Left for the Physician?
Skander Jemaa ... Richard A.D Carano
Journal of Clinical Oncology | VOL. -
Skander Jemaa, et. al.Skander Jemaa ... Richard A.D Carano
21 Jan 2025
Automatic for the People: What Has Machine Learning Analysis of Positron Emission Tomography Left for the Physician?
Vít Procházka ... Jaroslav Ptáček
Journal of Clinical Oncology | VOL. -
Vít Procházka, et. al.Vít Procházka ... Jaroslav Ptáček
21 Jan 2025
View more papers

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.